Patient demographics and baseline characteristics
. | VMP . | Historical MP . |
|---|---|---|
| No. patients | 60 | 96 |
| Median age, y (range) | 75 (65-85) | 73 (64-89) |
| 65 to 75 y, % | 53 | 67 |
| 76 to 80 y, % | 30 | 23 |
| Older than 80 y, % | 17 | 3 |
| Myeloma subtype, % | ||
| IgG | 59 | 48 |
| IgA | 34 | 33 |
| Bence-Jones | 7 | 14 |
| ISS stage, % | ||
| I | 29 | 24 |
| II | 54 | 54 |
| III | 17 | 22 |
| Median KPS (range) | 80 (60-100) | NA |
| 70 or below, % | 20 | 25 |
| 80, % | 47 | 38 |
| 90 or above, % | 32 | 36 |
| Albumin level below 3.5 g/dL, % | 20 | 36 |
| C-reactive protein level above 4 mg/L, % | 20 | 14 |
| LDH level above 460 U/L, % | 16 | 7 |
| β2-microglobulin level 297 nM or above, % | 54 | 39 |
| Bone marrow infiltration 50% or more, % | 35 | 27 |
. | VMP . | Historical MP . |
|---|---|---|
| No. patients | 60 | 96 |
| Median age, y (range) | 75 (65-85) | 73 (64-89) |
| 65 to 75 y, % | 53 | 67 |
| 76 to 80 y, % | 30 | 23 |
| Older than 80 y, % | 17 | 3 |
| Myeloma subtype, % | ||
| IgG | 59 | 48 |
| IgA | 34 | 33 |
| Bence-Jones | 7 | 14 |
| ISS stage, % | ||
| I | 29 | 24 |
| II | 54 | 54 |
| III | 17 | 22 |
| Median KPS (range) | 80 (60-100) | NA |
| 70 or below, % | 20 | 25 |
| 80, % | 47 | 38 |
| 90 or above, % | 32 | 36 |
| Albumin level below 3.5 g/dL, % | 20 | 36 |
| C-reactive protein level above 4 mg/L, % | 20 | 14 |
| LDH level above 460 U/L, % | 16 | 7 |
| β2-microglobulin level 297 nM or above, % | 54 | 39 |
| Bone marrow infiltration 50% or more, % | 35 | 27 |
The P value using the χ2 test and Fisher exact test was nonsignificant (P > .05) for every category.
ISS indicates International Staging System; KPS, Karnofsky performance status; LDH, lactate dehydrogenase; VMP, bortezomib plus melphalan plus prednisone; and NA, not available.